Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
 Your new post is loading...
Your new post is loading...
Scoop.it!
Healthcare giant Johnson & Johnson and its subsidiaries will pay more than $2.2 billion in criminal and civil fines to resolve allegations that it improperly promoted three drugs, including the antipsychotic drug Risperdal. 
No comment yet.
Sign up to comment
|
Scoop.it!
It is painful enough to have a child with a psychological disorder. To see that same child suffer physically due to the adverse affects of a defective medication is more than any parent should have to experience.
Matthew A. Dolman's insight:
It is painful enough to have a child with a psychological disorder. To see that same child suffer physically due to the adverse affects of a defective medication is more than any parent should have to experience. What if it was a male child who developed enlarged breasts and had to endure the trauma of having a radical mastectomy? This is an actual scenario that has been repeated countless times due to the adverse affects of a drug called Risperdal.
|
Healthcare giant Johnson & Johnson and its subsidiaries will pay more than $2.2 billion in criminal and civil fines to resolve allegations that it improperly promoted three drugs, including the antipsychotic drug Risperdal. The agreement represents the third-largest pharmaceutical settlement in United States history. Risperdal no longer has patent protection but it was once a best seller for Johnson & Johnson, accounting for $3.1 billion in sales in 2004 alone.
(click on the article above to learn more)